复星医药（600196）(02196)发布公告，2025年10月28日，公司董事会决议批准建议筹划公司附属公司 复星安特金(成都)生物制药有限公司(复星安特金)于香港联合交易所有限公司的分拆上市。 复星安特金成立于2012年7月。截至本公告日期，公司附属公司上海复星医药产业发展有限公司持有复 星安特金70.08%的股权，其他17方股东持有其剩余29.92%的股权。复星安特金及其附属公司专注于人 用疫苗的研发、生产及销售，已搭建细菌性疫苗和病毒性疫苗的技术平台。截至本公告日期，于中国内 地，其自主研发的人用狂犬病疫苗(Vero细胞)、冻干人用狂犬病疫苗(Vero细胞)、三价流感病毒裂解疫 苗及四价流感病毒裂解疫苗等产品已获批上市，其自主研发的13价肺炎球菌结合疫苗处于III期临床试验 阶段、其自主研发的冻干人用狂犬病疫苗(人二倍体细胞)及24价肺炎球菌多糖结合疫苗均处于I期临床试 验阶段、其自主研发的23价肺炎球菌多糖疫苗已获临床试验批准。 ...

Group 1 - The major shareholder Yuan Liping of Kangtai Biological plans to reduce her stake by no more than 1% of the company's total shares, which amounts to a maximum of 11,160,000 shares [1] - Yuan Liping directly holds 18.06% of the company's shares and indirectly holds 4.05% through other entities [1] - The company has faced significant performance declines in 2024, with revenue dropping by 23.75% to 2.652 billion yuan and net profit decreasing by 76.6% to 202 million yuan [2] Group 2 - In the first quarter of 2025, the company reported a revenue of 645 million yuan, a year-on-year increase of 42.85%, but the net profit attributable to the parent company fell by 58.51% to 22.43 million yuan [2] - The company’s accounts receivable at the end of 2024 stood at 2.787 billion yuan, representing 19.14% of total assets, and increased to 2.854 billion yuan by the end of the first quarter of 2025 [3] - Kangtai Biological is expanding its product pipeline to include vaccines for adults and is actively seeking to enter international markets, particularly in emerging markets and developing countries [3]

Buybacks and Shareholding Changes - Guizhou Moutai has repurchased 822,200 shares at a cost of 1.2 billion yuan [1] - SF Holding has repurchased 20,771,400 shares at a cost of 758 million yuan [1] - HeMai Co., Ltd. plans to increase its shareholding by 112 million to 223 million yuan [1] - Chipone Technology's controlling shareholder intends to increase its stake by 50 million to 100 million yuan [1] - Haitai New Light plans to repurchase shares worth 50 million to 100 million yuan [1] - Jiangnan Yifan's directors and shareholders plan to reduce their holdings by no more than 4% [1] - Maxinlin's shareholders plan to reduce their holdings by no more than 2% [1] - Wenke Co., Ltd. has a shareholder intending to reduce its holdings by no more than 1.6% [1] Mergers and Acquisitions - Jiabiou plans to acquire 63.21% of Ouyi Biological for 831 million yuan [1] - Guanghong Technology intends to acquire 100% of AC Company and 0.003% of TIS Company for 733 million yuan [1] - Youyan Silicon is planning a major asset restructuring to acquire 60% of Gaofeng Technology [1] - Chunhui Intelligent Control plans to acquire control of Chunhui Instrument [1] - Aerospace Electric plans to acquire 32.7% of Jiangsu Aolei for 56.933 million yuan [1] Operational Data - Lujiazui reported a net profit growth of 5.26% year-on-year for 2024 [1] - Chang'an Automobile's February sales reached 161,400 units, a year-on-year increase of 5.72% [1] - Ningbo Port completed a container throughput of 3.35 million TEUs in February, up 11% year-on-year [1] - Beibu Gulf Port's February cargo throughput was 23.9793 million tons, a year-on-year increase of 14.56% [1] Contracts and Bids - Hainan Huatie's subsidiary signed a 3.69 billion yuan computing power service agreement [1] - Jiahuan Technology is expected to win a China Mobile procurement project worth approximately 2.185 billion yuan [1] - Gansu Consulting's subsidiary won a bid for the modernization of the Gansu Province Jing Electric Irrigation District [1] - Hongrun Construction's subsidiary jointly won a 248 million yuan user-side energy storage project [1] - Yitong Century is expected to win a 228 million yuan project for China Mobile communication engineering [1] - Zhonglan Environmental Protection is expected to win a 167 million yuan ecological governance project for a landfill [1] - Sinan Navigation signed a major contract worth 145 million yuan [1] - Zhen Shitong won a project for the AV system of the China Merchants Bank headquarters [1] Major Investments - Panjiang Co., Ltd.'s wholly-owned subsidiary plans to invest 6.67 billion yuan in the construction of the Guizhou Energy Puding Power Plant [1] - Jinghua New Materials plans to invest 300 million yuan in the construction of a high-end adhesive material production and R&D center [1] - Sichuan Road and Bridge's subsidiary is participating in the investment of the Panzhihua to Yanyuan Expressway project [1] - Deyue Co., Ltd.'s Malaysian subsidiary signed a land sale agreement worth 194.3 million yuan [1] - Miao Exhibition plans to invest 101 million yuan in a fund [1] - Longtu Photomask plans to increase capital by 100 million yuan to its wholly-owned subsidiary Zhuhai Longtu [1] Other Developments - Berry Gene's AI-related business and products have not yet significantly impacted overall performance [1] - Agricultural Bank appointed Meng Fanjun as vice president [1] - Shanghai Bank's Niu Ren's director qualification has been approved [1] - China Life Insurance's Li Zhuyong resigned from executive director and vice president positions [1] - Fuling Power's chairman Lei Shanchun resigned due to personal work changes [1] - Houl娃 appointed Zhang Mingrui as general manager [1] - Ankai Micro launched a new generation of low-power Bluetooth chip AK1080 series [1] - San Da Membrane's Tiaonan investment project has begun trial operation [1] - Senying Windows triggered conditions to initiate stock price stabilization measures [1] - Aiwei Electronics successfully mass-produced its self-developed 4×80W automotive-grade digital audio amplifier products [1] - ST Haoyuan applied for the cancellation of its stock risk warning [1] - Huasheng Pharmaceutical's first special medical purpose formula food has obtained production license [1] - New Industry's products have received IVDR CE certification [1] - Yinuosi obtained CAP certification in the United States [1] - Changchun High-tech's subsidiary's drug has received approval for additional indications [1] - Fosun Pharma's 24-valent pneumococcal polysaccharide conjugate vaccine clinical trial has been approved [1]